ストックスクリーナーアプリを入手
0.00
100.00%
-0.55
前日終値:
$0.55
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$29.96M
収益：
$30.99M
当期純損益:
$-141.41M
株価収益率:
0.00
EPS:
-2.63
ネットキャッシュフロー:
$-118.12M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$1.97
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
名前
Marinus Pharmaceuticals Inc
セクター
電話
484-801-4670
住所
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
MRNS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.00 | 29.96M | 30.99M | -141.41M | -118.12M | -2.63 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-08-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2024-04-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-04-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-01-20 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-09-30 | 開始されました | Truist | Buy |
| 2020-07-01 | 開始されました | Cowen | Outperform |
| 2020-07-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-09 | 開始されました | Craig Hallum | Buy |
| 2019-12-20 | 開始されました | Oppenheimer | Outperform |
| 2019-03-05 | 再開されました | Jefferies | Buy |
| 2019-02-27 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-02-06 | 開始されました | Leerink Partners | Outperform |
| 2018-07-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-03-20 | 開始されました | Mizuho | Buy |
| 2018-02-15 | 開始されました | H.C. Wainwright | Buy |
| 2017-12-14 | 開始されました | Laidlaw | Buy |
| 2016-08-10 | 繰り返されました | Jefferies | Buy |
| 2016-06-14 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | 繰り返されました | Stifel | Buy |
| 2015-12-17 | 開始されました | RBC Capital Mkts | Outperform |
| 2015-11-17 | 開始されました | Jefferies | Buy |
| 2015-10-30 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-05 | 繰り返されました | Oppenheimer | Outperform |
すべてを表示
Marinus Pharmaceuticals Inc (MRNS) 最新ニュース
Shareholders that Lost Money on Marinus Pharmaceuticals, Inc. (MRNS) Should Contact Levi & Korsinsky About Pending Class ActionMRNS - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com - Defense World
Can The RAISE Study Data Give Marinus' Stock A Boost? - RTTNews
FINAL MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Purchases 354,393 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc.(MRNS) Shareholders - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Shareholders - ACCESS Newswire
Kiniksa Pharmaceuticals (NASDAQ:KNSA) versus Marinus Pharmaceuticals (NASDAQ:MRNS) Financial Analysis - Defense World
Fragile X Syndrome Market to Show Remarkable Growth Trends from - openPR.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus - MarketScreener
Marinus pharmaceuticals director sells shares for $864 - MSN
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire - The Globe and Mail
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Refractory Status Epilepticus Treatment Market Size in 7MM - openPR.com
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Developmental and Epileptic Encephalopathies Treatment - openPR.com
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com - Armenian Reporter
MRNS LAWSUIT ALERT: Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNS - ACCESS Newswire
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: - openPR
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals director sells shares worth $869 - MSN
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - MSN
Tuberous Sclerosis Complex Therapeutics Market Size Report - openPR
IMMINENT MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB - Defense World
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock By Investing.com - Investing.com UK
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Marinus Pharmaceuticals, Inc.Common Stock (NQ: MRNS - FinancialContent
Marinus Pharmaceuticals Inc (MRNS) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
大文字化:
|
ボリューム (24 時間):